-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 1, Innovent and Baoyuan Medicine jointly announced that Taletrectinib has been included in the list of breakthrough therapy drugs by CDE.
Talatinib is a new generation of ROS1 and NTRK highly selective and potent tyrosine kinase inhibitors under investigation, which can cross the blood-brain barrier
In June 2021, Innovent Bio obtained the rights to jointly develop and commercialize the drug with Baoyuan Pharma in Greater China (including mainland China, Hong Kong, Macau and Taiwan) for a total amount of US$189 million